{
    "hands_on_practices": [
        {
            "introduction": "The primary motivation for choosing a crossover design is its superior statistical efficiency compared to a parallel-group study. This efficiency arises because each participant serves as their own control, which effectively removes the between-subject variability from the treatment comparison. This first exercise  provides hands-on practice in calculating the required sample size for a $2 \\times 2$ crossover trial, connecting the desired effect size, data variability, and statistical power to the number of participants needed.",
            "id": "5038503",
            "problem": "A translational medicine team is planning a balanced two-period, two-treatment crossover study (sequence groups $A \\rightarrow B$ and $B \\rightarrow A$) to compare two formulations of a biologic acting on a pharmacodynamic biomarker. The primary endpoint is a continuous biomarker measured once per period per subject, and the treatment effect is defined as the mean difference $A - B$, denoted by $\\Delta$. In a pilot, the within-subject residual variance per period was estimated as $\\sigma_{w}^{2}$ and carryover effects were found to be negligible. For planning, assume no carryover, negligible period and sequence effects, and independent, identically distributed residuals per period with variance $\\sigma_{w}^{2}$.\n\nUsing the Central Limit Theorem (CLT) and a large-sample normal approximation for the two-sided test of $H_{0}:\\Delta=0$ versus $H_{1}:\\Delta \\neq 0$, compute the required total number of subjects $N$ for the crossover study to detect $\\Delta = 0.5$ with within-subject variance $\\sigma_{w}^{2} = 1.0$, type I error rate $\\alpha = 0.05$ (two-sided), and power $0.9$. Treat $N$ as a real-valued planning quantity (do not round to an integer). Round your final numeric answer to four significant figures.",
            "solution": "The user wants to compute the required total number of subjects, $N$, for a balanced two-period, two-treatment crossover study.\n\n### Step 1: Problem Validation\n\n**1. Extract Givens**\n- Study Design: Balanced two-period, two-treatment ($A, B$) crossover study.\n- Sequence Groups: Sequence 1 ($A \\rightarrow B$) and Sequence 2 ($B \\rightarrow A$).\n- Total Subjects: $N$, with $n = N/2$ subjects per sequence group.\n- Endpoint: Continuous biomarker.\n- Treatment Effect of Interest: $\\Delta = E[Y_A] - E[Y_B]$.\n- Assumptions: No carryover, negligible period and sequence effects.\n- Statistical Model: Independent, identically distributed residuals per period with variance $\\sigma_{w}^{2}$.\n- Hypothesis Test: Two-sided test of $H_{0}: \\Delta = 0$ versus $H_{1}: \\Delta \\neq 0$.\n- Method: Central Limit Theorem (CLT) and large-sample normal approximation.\n- Parameters for Calculation:\n    - Target effect size to detect: $\\Delta = 0.5$.\n    - Within-subject variance: $\\sigma_{w}^{2} = 1.0$.\n    - Type I error rate: $\\alpha = 0.05$ (two-sided).\n    - Power: $1 - \\beta = 0.9$.\n- Output Requirement: Compute $N$ as a continuous value and round to four significant figures.\n\n**2. Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is well-grounded in the statistical theory of clinical trial design. All concepts (crossover design, power, sample size, type I error, variance components) are standard in biostatistics and translational medicine.\n- **Well-Posed**: The problem is well-posed. It requests the calculation of a single quantity ($N$) based on a complete set of specified parameters and a clearly defined statistical model. A unique solution exists.\n- **Objective**: The problem is stated in objective, quantitative terms, free from any subjectivity or ambiguity.\n- **Completeness and Consistency**: All necessary data ($\\Delta, \\sigma_w^2, \\alpha, 1-\\beta$) are provided. The assumptions (e.g., no carryover) are explicitly stated for the purpose of planning, which is a standard practical simplification. There are no contradictions.\n- **Feasibility**: The parameter values are realistic for a biomedical study. The calculation is standard.\nThe problem is a standard, non-trivial textbook exercise in biostatistics.\n\n**3. Verdict and Action**\n- The problem is valid. The solution will proceed.\n\n### Step 2: Derivation of the Sample Size Formula\n\nLet $Y_{ijk}$ be the observation for subject $i$ ($i = 1, \\dots, n$) in sequence group $j$ ($j=1, 2$) during period $k$ ($k=1, 2$). The total number of subjects is $N = 2n$. The statistical model for the observation, assuming no sequence effect, is:\n$Y_{ijk} = \\mu + S_{ij} + P_k + T_{t(j,k)} + \\epsilon_{ijk}$\nwhere $\\mu$ is the overall mean, $S_{ij}$ is the random effect of subject $i$ in sequence $j$, $P_k$ is the fixed effect of period $k$, $T_{t(j,k)}$ is the fixed effect of the treatment, and $\\epsilon_{ijk}$ is the within-subject random error with $\\text{Var}(\\epsilon_{ijk}) = \\sigma_{w}^{2}$.\n\nAn unbiased estimator for the treatment effect $\\Delta$ that adjusts for period effects is $\\hat{\\Delta} = \\frac{1}{2}(\\bar{D}_2 - \\bar{D}_1)$, where $\\bar{D}_j$ is the mean of the within-subject period differences $Y_{ij2} - Y_{ij1}$ for sequence group $j$. The variance of this estimator is:\n$\\text{Var}(\\hat{\\Delta}) = \\frac{2\\sigma_{w}^{2}}{N}$\n\nFor a large sample size, $\\hat{\\Delta}$ is approximately normally distributed. For a two-sided test with type I error $\\alpha$ and power $1-\\beta$ to detect a true difference of $\\Delta$, the required total sample size $N$ can be derived from the standard formula:\n$$ N = \\frac{2\\sigma_{w}^{2}(z_{1-\\alpha/2} + z_{1-\\beta})^2}{\\Delta^2} $$\nwhere $z_{q}$ is the $q$-th quantile of the standard normal distribution.\n\n### Step 3: Calculation\n\nThe given parameters are:\n- $\\Delta = 0.5$\n- $\\sigma_{w}^{2} = 1.0$\n- $\\alpha = 0.05$ (two-sided)\n- $1 - \\beta = 0.9 \\implies \\beta = 0.1$\n\nWe need the corresponding quantiles (z-scores) from the standard normal distribution:\n- For the type I error rate: $z_{1-\\alpha/2} = z_{1-0.05/2} = z_{0.975}$. This value is approximately $1.95996$.\n- For the power: $z_{1-\\beta} = z_{1-0.1} = z_{0.9}$. This value is approximately $1.28155$.\n\nNow, we substitute these values into the sample size formula:\n$N = \\frac{2(1.0)(1.95996 + 1.28155)^2}{(0.5)^2}$\n$N = \\frac{2(3.24151)^2}{0.25}$\n$N = 8 \\times (3.24151)^2$\n$N = 8 \\times 10.50738$\n$N \\approx 84.05904$\n\nThe problem requires rounding the final numeric answer to four significant figures.\n$N \\approx 84.06$",
            "answer": "$$\\boxed{84.06}$$"
        },
        {
            "introduction": "The statistical efficiency of a crossover design, as demonstrated in the sample size calculation , is contingent upon the critical assumption that the effect of the treatment from one period does not \"carry over\" to the next. Ensuring this assumption holds is a crucial aspect of trial design. This practice  focuses on a key practical tool for mitigating carryover: the washout period. You will calculate the minimum required duration for this period based on fundamental pharmacokinetic principles, providing a direct link between a drug's biological properties and the structural integrity of the clinical trial.",
            "id": "5038383",
            "problem": "In a translational medicine early-phase study, a two-period, two-sequence within-subject crossover design is proposed to compare a novel anti-inflammatory agent against placebo. To mitigate carryover effects between periods, the washout interval must be chosen such that the residual drug concentration at the start of the second period is practically negligible relative to the first periodâ€™s peak following a single oral dose. Assume first-order elimination pharmacokinetics, a single dose administered per period, and that the terminal half-life is $t_{1/2} = 12$ h. Determine the minimum washout duration required so that the residual concentration at the beginning of the second period is below a fraction $0.01$ of the peak concentration observed after the dose in the first period. Express your answer in hours and round to four significant figures.",
            "solution": "The user has provided a problem asking for the minimum washout duration in a two-period crossover clinical trial. First, the validity of the problem statement will be assessed.\n\n### Step 1: Extract Givens\n- **Study Design**: Two-period, two-sequence within-subject crossover design.\n- **Pharmacokinetic Model**: First-order elimination.\n- **Dosing**: Single oral dose per period.\n- **Terminal Half-Life**: $t_{1/2} = 12$ h.\n- **Washout Criterion**: The residual drug concentration at the start of the second period must be below a fraction $f = 0.01$ of the peak concentration ($C_{peak}$) observed in the first period.\n- **Required Output**: Minimum washout duration ($t_w$) in hours, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is well-grounded in the principles of pharmacokinetics, specifically first-order elimination, which is a standard model for drug clearance. The concept of a washout period to minimize carryover effects is fundamental to the design of crossover studies in clinical pharmacology and translational medicine.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary parameters ($t_{1/2}$, target residual fraction) and a clear objective (calculate minimum $t_w$) to arrive at a unique, meaningful solution.\n- **Objectivity**: The problem is stated using precise, objective scientific terminology.\n- **Completeness and Consistency**: The information is sufficient and internally consistent. The use of a single-compartment model with first-order elimination following the peak concentration is a standard and appropriate simplification for this type of calculation.\n- **Realism**: The value for the half-life ($t_{1/2} = 12$ h) is realistic for many pharmaceutical compounds. The requirement to reduce concentration to $1\\%$ of the peak is a common and stringent criterion for ensuring adequate washout.\n\n### Step 3: Verdict and Action\nThe problem is scientifically valid, well-posed, and contains sufficient information for a unique solution. The solution process may proceed.\n\n### Solution Derivation\nThe concentration of a drug, $C(t)$, that undergoes first-order elimination decreases over time according to the exponential decay model. We measure time $t$ starting from the point at which the peak concentration, $C_{\\text{peak}}$, is achieved. The concentration at any subsequent time $t$ is given by:\n$$C(t) = C_{\\text{peak}} \\exp(-k_e t)$$\nwhere $k_e$ is the first-order elimination rate constant.\n\nThe elimination rate constant $k_e$ is related to the drug's terminal half-life, $t_{1/2}$. By definition, the half-life is the time required for the concentration to decrease to $50\\%$ of its initial value. Therefore, at $t = t_{1/2}$:\n$$C(t_{1/2}) = \\frac{1}{2} C_{\\text{peak}}$$\nSubstituting this into the decay equation:\n$$\\frac{1}{2} C_{\\text{peak}} = C_{\\text{peak}} \\exp(-k_e t_{1/2})$$\nDividing by $C_{\\text{peak}}$ (which is non-zero) gives:\n$$\\frac{1}{2} = \\exp(-k_e t_{1/2})$$\nTaking the natural logarithm of both sides:\n$$\\ln\\left(\\frac{1}{2}\\right) = -k_e t_{1/2}$$\nUsing the logarithm property $\\ln(1/x) = -\\ln(x)$:\n$$-\\ln(2) = -k_e t_{1/2}$$\nSolving for $k_e$ yields:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}}$$\n\nThe problem requires finding the minimum washout duration, $t_w$, such that the residual concentration at the start of the second period, $C(t_w)$, is below a fraction $f = 0.01$ of the peak concentration from the first period. This can be expressed as an inequality:\n$$C(t_w) \\le f \\cdot C_{\\text{peak}}$$\nSubstituting the expression for $C(t_w)$:\n$$C_{\\text{peak}} \\exp(-k_e t_w) \\le f \\cdot C_{\\text{peak}}$$\nWe can divide by $C_{\\text{peak}}$ since it is a positive concentration:\n$$\\exp(-k_e t_w) \\le f$$\nTo solve for $t_w$, we take the natural logarithm of both sides. As the natural logarithm is a strictly increasing function, the inequality direction is preserved:\n$$\\ln(\\exp(-k_e t_w)) \\le \\ln(f)$$\n$$-k_e t_w \\le \\ln(f)$$\nMultiplying by $-1$ reverses the inequality sign:\n$$k_e t_w \\ge -\\ln(f)$$\nUsing the logarithm property $-\\ln(f) = \\ln(1/f)$:\n$$k_e t_w \\ge \\ln\\left(\\frac{1}{f}\\right)$$\nIsolating $t_w$:\n$$t_w \\ge \\frac{\\ln(1/f)}{k_e}$$\nThis expression gives the minimum required washout duration. Now, we substitute the expression for $k_e$:\n$$t_w \\ge \\frac{\\ln(1/f)}{\\frac{\\ln(2)}{t_{1/2}}}$$\n$$t_w \\ge t_{1/2} \\cdot \\frac{\\ln(1/f)}{\\ln(2)}$$\nThe minimum washout duration, $t_{w,min}$, is the lower bound of this inequality.\n\nWe are given the values $t_{1/2} = 12$ h and $f = 0.01$. Substituting these into the expression for the minimum washout duration:\n$$t_{w,min} = 12 \\text{ h} \\cdot \\frac{\\ln(1/0.01)}{\\ln(2)}$$\n$$t_{w,min} = 12 \\cdot \\frac{\\ln(100)}{\\ln(2)}$$\nNow, we compute the numerical value:\n$$t_{w,min} = 12 \\cdot \\frac{4.60517018598...}{0.69314718056...}$$\n$$t_{w,min} = 12 \\cdot 6.64385618977...$$\n$$t_{w,min} \\approx 79.726274277... \\text{ h}$$\nThe problem requires the answer to be rounded to four significant figures.\n$$t_{w,min} \\approx 79.73 \\text{ h}$$",
            "answer": "$$\n\\boxed{79.73}\n$$"
        },
        {
            "introduction": "While a properly designed washout period can minimize carryover, it is essential to understand the analytical consequences if this assumption is violated. A naive analysis of a crossover study with unaddressed carryover can lead to misleading conclusions about a treatment's efficacy. This final exercise  transitions from practical calculation to theoretical derivation, challenging you to quantify the exact bias introduced into the treatment effect estimate when a differential carryover effect is present. Completing this derivation provides a deeper, mathematical appreciation for why the no-carryover assumption is fundamental to the validity of this powerful study design.",
            "id": "5038507",
            "problem": "A pharmacodynamic biomarker is compared between a novel small-molecule inhibitor (treatment $A$) and placebo (treatment $B$) in a balanced $2 \\times 2$ crossover study in translational medicine. Subjects are randomized equally to sequence $AB$ or $BA$, and each subject is observed in period $1$ and period $2$. Let $Y_{i,s,p}$ denote the outcome for subject $i$ in sequence $s \\in \\{AB, BA\\}$ and period $p \\in \\{1,2\\}$. Assume the standard linear additive model with subject-specific random intercepts:\n$$\nY_{i,s,p} \\;=\\; \\mu \\;+\\; b_i \\;+\\; \\pi_p \\;+\\; \\tau_{T(s,p)} \\;+\\; \\kappa_{s,p} \\;+\\; \\varepsilon_{i,s,p},\n$$\nwhere $\\mu$ is a grand mean, $b_i$ is a subject effect with $\\mathbb{E}[b_i]=0$, $\\pi_p$ is a period effect, $\\tau_{T(s,p)}$ is the direct treatment effect for the treatment actually administered in that sequence and period, $\\kappa_{s,p}$ is a carryover term that affects only period $2$, and $\\varepsilon_{i,s,p}$ are independent mean-zero errors with constant variance that are independent of all design factors. Define the true direct treatment contrast of scientific interest as $\\delta = \\tau_A - \\tau_B$.\n\nSuppose there is first-order differential carryover confined to period $2$ such that if a subject received treatment $T \\in \\{A,B\\}$ in period $1$, then $\\kappa_{s,2} = c_T$ in period $2$ for that subject, and $\\kappa_{s,1}=0$ in period $1$. Define the magnitude of differential carryover as $c = c_A - c_B$.\n\nInvestigators perform a naive analysis that ignores carryover and period effects by estimating the treatment contrast with the difference of marginal means across all periods:\n$$\n\\hat{\\delta} \\;=\\; \\bar{Y}_A \\;-\\; \\bar{Y}_B,\n$$\nwhere $\\bar{Y}_A$ is the sample mean of all outcomes observed under treatment $A$ (pooling across sequences and periods), and $\\bar{Y}_B$ is defined analogously for treatment $B$. Under the assumptions above and balanced allocation to sequences, derive the bias of $\\hat{\\delta}$ for $\\delta$ as a function of $c$. Express your final answer as a single closed-form analytic expression in terms of $c$. No numerical rounding is required.",
            "solution": "The problem requires the derivation of the bias of a naive estimator for the treatment contrast in a $2 \\times 2$ crossover study. The bias of an estimator $\\hat{\\theta}$ for a parameter $\\theta$ is defined as $\\mathbb{E}[\\hat{\\theta}] - \\theta$. In this problem, the estimator is $\\hat{\\delta}$ and the parameter of interest is $\\delta$. Thus, we need to calculate $\\mathbb{E}[\\hat{\\delta}] - \\delta$.\n\nThe naive estimator is given by $\\hat{\\delta} = \\bar{Y}_A - \\bar{Y}_B$, where $\\bar{Y}_A$ and $\\bar{Y}_B$ are the sample means of all outcomes observed under treatments $A$ and $B$, respectively. By the linearity of expectation, the expected value of the estimator is $\\mathbb{E}[\\hat{\\delta}] = \\mathbb{E}[\\bar{Y}_A] - \\mathbb{E}[\\bar{Y}_B]$.\n\nLet $N$ be the total number of subjects in the study. The design is balanced, so $N/2$ subjects are randomized to sequence $AB$ and $N/2$ are randomized to sequence $BA$. Let $S_{AB}$ denote the set of subjects in sequence $AB$ and $S_{BA}$ denote the set of subjects in sequence $BA$. We have $|S_{AB}| = |S_{BA}| = N/2$.\n\nThe total number of observations under treatment $A$ is $N$. These observations come from subjects in sequence $AB$ during period $1$ and subjects in sequence $BA$ during period $2$. The sample mean $\\bar{Y}_A$ is therefore:\n$$\n\\bar{Y}_A = \\frac{1}{N} \\left( \\sum_{i \\in S_{AB}} Y_{i,AB,1} + \\sum_{i \\in S_{BA}} Y_{i,BA,2} \\right)\n$$\nSimilarly, the total number of observations under treatment $B$ is also $N$. These observations come from subjects in sequence $BA$ during period $1$ and subjects in sequence $AB$ during period $2$. The sample mean $\\bar{Y}_B$ is:\n$$\n\\bar{Y}_B = \\frac{1}{N} \\left( \\sum_{i \\in S_{BA}} Y_{i,BA,1} + \\sum_{i \\in S_{AB}} Y_{i,AB,2} \\right)\n$$\nNext, we find the expected value of an individual observation, $Y_{i,s,p}$, using the given linear model:\n$$\nY_{i,s,p} = \\mu + b_i + \\pi_p + \\tau_{T(s,p)} + \\kappa_{s,p} + \\varepsilon_{i,s,p}\n$$\nTaking the expectation and using the assumptions $\\mathbb{E}[b_i]=0$ and $\\mathbb{E}[\\varepsilon_{i,s,p}]=0$, we get:\n$$\n\\mathbb{E}[Y_{i,s,p}] = \\mu + \\pi_p + \\tau_{T(s,p)} + \\kappa_{s,p}\n$$\nWe apply this formula to the four specific conditions in the study:\n$1$. For subjects in sequence $AB$ ($s=AB$), period $1$ ($p=1$): The treatment is $A$, so $T(AB,1)=A$. The carryover term is $\\kappa_{AB,1}=0$.\n$$ \\mathbb{E}[Y_{i,AB,1}] = \\mu + \\pi_1 + \\tau_A $$\n$2$. For subjects in sequence $AB$ ($s=AB$), period $2$ ($p=2$): The treatment is $B$, so $T(AB,2)=B$. The carryover is from treatment $A$ in period $1$, so $\\kappa_{AB,2}=c_A$.\n$$ \\mathbb{E}[Y_{i,AB,2}] = \\mu + \\pi_2 + \\tau_B + c_A $$\n$3$. For subjects in sequence $BA$ ($s=BA$), period $1$ ($p=1$): The treatment is $B$, so $T(BA,1)=B$. The carryover term is $\\kappa_{BA,1}=0$.\n$$ \\mathbb{E}[Y_{i,BA,1}] = \\mu + \\pi_1 + \\tau_B $$\n$4$. For subjects in sequence $BA$ ($s=BA$), period $2$ ($p=2$): The treatment is $A$, so $T(BA,2)=A$. The carryover is from treatment $B$ in period $1$, so $\\kappa_{BA,2}=c_B$.\n$$ \\mathbb{E}[Y_{i,BA,2}] = \\mu + \\pi_2 + \\tau_A + c_B $$\nNow we can compute the expected values of the sample means $\\bar{Y}_A$ and $\\bar{Y}_B$.\n$$\n\\mathbb{E}[\\bar{Y}_A] = \\frac{1}{N} \\left( \\sum_{i \\in S_{AB}} \\mathbb{E}[Y_{i,AB,1}] + \\sum_{i \\in S_{BA}} \\mathbb{E}[Y_{i,BA,2}] \\right)\n$$\nSince the expected value is the same for all subjects within a given sequence and period, we have:\n$$\n\\mathbb{E}[\\bar{Y}_A] = \\frac{1}{N} \\left( |S_{AB}| \\cdot \\mathbb{E}[Y_{i,AB,1}] + |S_{BA}| \\cdot \\mathbb{E}[Y_{i,BA,2}] \\right)\n$$\nSubstituting $|S_{AB}| = |S_{BA}| = N/2$ and the expressions for the expected values:\n$$\n\\mathbb{E}[\\bar{Y}_A] = \\frac{1}{N} \\left( \\frac{N}{2}(\\mu + \\pi_1 + \\tau_A) + \\frac{N}{2}(\\mu + \\pi_2 + \\tau_A + c_B) \\right)\n$$\n$$\n\\mathbb{E}[\\bar{Y}_A] = \\frac{1}{2}(\\mu + \\pi_1 + \\tau_A) + \\frac{1}{2}(\\mu + \\pi_2 + \\tau_A + c_B) = \\mu + \\tau_A + \\frac{\\pi_1 + \\pi_2}{2} + \\frac{c_B}{2}\n$$\nSimilarly, for $\\bar{Y}_B$:\n$$\n\\mathbb{E}[\\bar{Y}_B] = \\frac{1}{N} \\left( \\sum_{i \\in S_{BA}} \\mathbb{E}[Y_{i,BA,1}] + \\sum_{i \\in S_{AB}} \\mathbb{E}[Y_{i,AB,2}] \\right)\n$$\n$$\n\\mathbb{E}[\\bar{Y}_B] = \\frac{1}{N} \\left( |S_{BA}| \\cdot \\mathbb{E}[Y_{i,BA,1}] + |S_{AB}| \\cdot \\mathbb{E}[Y_{i,AB,2}] \\right)\n$$\n$$\n\\mathbb{E}[\\bar{Y}_B] = \\frac{1}{N} \\left( \\frac{N}{2}(\\mu + \\pi_1 + \\tau_B) + \\frac{N}{2}(\\mu + \\pi_2 + \\tau_B + c_A) \\right)\n$$\n$$\n\\mathbb{E}[\\bar{Y}_B] = \\frac{1}{2}(\\mu + \\pi_1 + \\tau_B) + \\frac{1}{2}(\\mu + \\pi_2 + \\tau_B + c_A) = \\mu + \\tau_B + \\frac{\\pi_1 + \\pi_2}{2} + \\frac{c_A}{2}\n$$\nNow we find the expectation of the estimator $\\hat{\\delta}$:\n$$\n\\mathbb{E}[\\hat{\\delta}] = \\mathbb{E}[\\bar{Y}_A] - \\mathbb{E}[\\bar{Y}_B]\n$$\n$$\n\\mathbb{E}[\\hat{\\delta}] = \\left( \\mu + \\tau_A + \\frac{\\pi_1 + \\pi_2}{2} + \\frac{c_B}{2} \\right) - \\left( \\mu + \\tau_B + \\frac{\\pi_1 + \\pi_2}{2} + \\frac{c_A}{2} \\right)\n$$\nThe terms $\\mu$ and $\\frac{\\pi_1 + \\pi_2}{2}$ cancel out:\n$$\n\\mathbb{E}[\\hat{\\delta}] = (\\tau_A - \\tau_B) + (\\frac{c_B}{2} - \\frac{c_A}{2}) = (\\tau_A - \\tau_B) - \\frac{1}{2}(c_A - c_B)\n$$\nUsing the definitions provided, $\\delta = \\tau_A - \\tau_B$ and $c = c_A - c_B$. We can write:\n$$\n\\mathbb{E}[\\hat{\\delta}] = \\delta - \\frac{c}{2}\n$$\nFinally, the bias of $\\hat{\\delta}$ is:\n$$\n\\text{Bias}(\\hat{\\delta}) = \\mathbb{E}[\\hat{\\delta}] - \\delta = \\left(\\delta - \\frac{c}{2}\\right) - \\delta = -\\frac{c}{2}\n$$\nThe bias of the naive estimator is $-\\frac{1}{2}$ times the magnitude of the differential carryover effect.",
            "answer": "$$\n\\boxed{-\\frac{c}{2}}\n$$"
        }
    ]
}